Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Biotechnology Cancer Cures -- Ignore unavailable to you. Want to Upgrade?

To: mike head who wrote (26)	4/15/1999 12:31:00 AM
From: SnowShredder	Read Replies (1) \| Respond to of 226

Hi Mike, I think that Onyx-O15 has some good results in humans...unlike ENMD still in mice. The mechanism of selective replication in p53- cells is questionable, but it works. Which it should considering they are using an adenovirus...as the virus replicates in the cell, the cell produces some immunogenic viral proteins that cause the host's immune system to attack the infected cell...so if the virus doesn't kill the cell (adenovirus is a lytic virus...in that it fills the interior of the cell with viral progeny, and then lyses the cell...kinda like filling up a water balloon til it pops), the immune response should. For long term investing purposes, it is hard to buy in on news, unless you have good execution and timing, because good releases stocks usually spike and then retrace. My advice is try to position yourself accordingly b4 the news release...I shoulda, but didn't...next time. I might try to flip it tomorrow, but I'll probably just watch. Best of Luck, Where'd He Go?

To: mike head who wrote (26)	7/5/1999 9:23:00 PM
From: mike head	Respond to of 226

To all. An extremely positive 20 min.+ _ on CNN about ONXX. McCormick comes across well-- whole segment upbeat, and prolly will add 50%+ to stock value tomorrow- which saddens me, in a way! The CNN segment did NOT dwell dwell on the point that although the P53 supressor gene idea,was indeed a brilliant one, the success of the trial appears to indicate some other mechanism in play for the tumor reduction. Sic Transit Gloria...! pax et bonum, mch